Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 188 people in total — 95 in a group that received a combination of two medicines (PEG-IFN Alfa-2a and Ribavirin) for 24 weeks, and 93 in a group that received the same combination for 48 weeks. The trial was measuring whether the hepatitis C virus became undetectable in participants' blood and stayed that way after treatment finished — a result researchers call a "sustained virological response," which simply means the virus could no longer be detected in a blood test taken well after the treatment course ended. The reported data shows that, for the main result measured 24 weeks after the scheduled end of treatment, 52% of people in the 24-week group and 57% of people in the 48-week group had undetectable virus levels. For a slightly different version of this same main measure — taken 24 weeks after each person's actual last dose (which could differ if someone stopped early) — the figures were 52% for the 24-week group and 61% for the 48-week group. When virus levels were checked at the moment treatment finished, 93% of the 24-week group and 90% of the 48-week group had undetectable virus at that point. However, among those who had undetectable virus at the end of treatment, a portion later showed the virus returning — this was reported as 41% of the 24-week group and 29% of the 48-week group. At 72 weeks after the start of treatment, 44% of the 24-week group and 57% of the 48-week group still had undetectable virus levels. Results at 12 weeks after the actual end of treatment were also reported, showing 52% and 61% respectively — the same figures as the 24-week post-treatment measurement. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Hepatitis C Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older
- You must have blood test results showing you have chronic (long-term) hepatitis C
- Your hepatitis C must be a specific type, called genotype 2 or 3
- You must currently be receiving treatment with PEGASYS and Copegus (two specific hepatitis C medications) as part of your standard care, and the virus must not have fully cleared from your blood after the first 4 weeks of treatment
- Your liver must still be functioning reasonably well (described as "compensated")
Who may not be able to join:
- You have previously received treatment with pegylated interferon, standard interferon, or ribavirin (hepatitis C medicines) at any time before starting your current PEGASYS and Copegus treatment
- You also have hepatitis A, hepatitis B, or HIV alongside your hepatitis C
- You have a history of, or current signs of, serious liver complications where the liver is no longer able to function properly (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment; Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.